Drug Discovery

Loading the player...

Results: ORION-9 with Frederick Raal, PhD

Derick Raal, PhD, principal Investigator of the ORION-9 trial provides a brief overview of the results and their significance for patients with familial hypercholesterolemia. Dr. Raal is on the faculty of Health Sciences at the University of the Witwatersrand in Johannesburg, South Africa. See this study and other late-breaking science presentations on our AHA Science News page.

Science NewsView All Science News

Heart Disease and Stroke Statistics - 2020 Update
01/29/2020 | The age-adjusted death rate attributable to cardiovascular disease (CVD), based on 2017 data, is 219.4 per 100,000.
The AHA 2030 Impact Goal
01/29/2020 | Since the late 1990s, the AHA has committed to a singular impact goal to advance the AHA?s mission for the decade ahead.
ATVB | Featured Articles | February 2020
01/29/2020 | ATVB January 2020 Editor's Pick and Featured Article
CIRCULATION Editor's Picks | January 2020
01/28/2020 | CIRCULATON Editor's Picks for January 2020

Related Councils

Council on Arteriosclerosis, Thrombosis and Vascular Biology (ATVB)

Mary Sorci-Thomas, PhD, FAHA

The Council on Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) contributes to the mission and objectives of the American Heart Association (AHA) through efforts in the fields of arteriosclerosis, thrombosis and vascular biology. The council advances and coordinates research, addresses prevention, improves methods for diagnosis and treatment, and works actively with other organizations concerned with these issues. The council disseminates reliable information related to these fields through its annual conference, many awards and lectures, and the AHA's journal, Arteriosclerosis, Thrombosis, and Vascular Biology.

Mary Sorci-Thomas, PhD, FAHA
Chair, Council on Arteriosclerosis, Thrombosis and Vascular Biology

Vascular Discovery Scientific Sessions       Arteriosclerosis, Thrombosis, and Vascular Biology       ATVB Council Awards

Council on Clinical Cardiology (CLCD)

Eldrin Lewis, MD, MPH, FAHA, FACC

The purpose of the Council on Clinical Cardiology (CLCD) is to achieve the objectives of the American Heart Association (AHA) in the field of clinical cardiology, to promote excellence in clinical care and to foster the professional development and education of clinical cardiologists. Through council-sponsored symposia, panels and scientific conferences, members can access new developments in the field and interpret and promote clinical cardiology to professional and lay audiences.

Eldrin Lewis, MD, MPH, FAHA, FACC
Chair, Council on Clinical Cardiology

Scientific Sessions       Circulation       CLCD Council Awards

Council on Genomic and Precision Medicine (GPM)

Thomas J. Wang, MD, FAHA

The mission of the American Heart Association Council on Genomic and Precision Medicine (GPM) is to advance the discovery and translation of biological insights gained from genetics and omics technologies to improve cardiovascular and brain health. Our constituency’s expertise spans across genetics, genomics, epigenetics, transcriptomics, metabolomics, proteomics, microbiome, bioinformatics, computational science, population health, clinical genetics and genomic medicine, with the ultimate goal of more precise risk prediction, treatment and prevention for patients and the population. Integral to the American Heart Association’s goals, the GPM Council provides a premier inter-disciplinary forum promoting and integrating new knowledge from molecules to populations in translational cardiovascular science and precision medicine.

Thomas J. Wang, MD, FAHA
Chair, Council on Genomic and Precision Medicine

Scientific Sessions       Circulation: Genomic and Precision Medicine      GPM Council Awards